Your browser is no longer supported. Please, upgrade your browser.
DRNA Dicerna Pharmaceuticals, Inc. daily Stock Chart
DRNA [NASD]
Dicerna Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.48 Insider Own0.10% Shs Outstand69.14M Perf Week-6.34%
Market Cap1.42B Forward P/E- EPS next Y-0.13 Insider Trans-98.88% Shs Float62.90M Perf Month1.99%
Income-99.40M PEG- EPS next Q0.55 Inst Own88.90% Short Float5.18% Perf Quarter-4.07%
Sales18.40M P/S77.11 EPS this Y56.40% Inst Trans-0.89% Short Ratio4.06 Perf Half Y54.05%
Book/sh1.97 P/B10.42 EPS next Y80.60% ROA-26.70% Target Price31.50 Perf Year96.74%
Cash/sh4.52 P/C4.54 EPS next 5Y- ROE-58.90% 52W Range10.15 - 27.68 Perf YTD-6.85%
Dividend- P/FCF20.12 EPS past 5Y4.10% ROI-45.00% 52W High-25.98% Beta2.59
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low101.87% ATR0.95
Employees78 Current Ratio2.70 Sales Q/Q433.30% Oper. Margin- RSI (14)45.94 Volatility4.58% 4.55%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.80% Profit Margin- Rel Volume0.45 Prev Close20.52
ShortableYes LT Debt/Eq0.00 EarningsMar 09 AMC Payout- Avg Volume803.29K Price20.49
Recom1.60 SMA200.84% SMA50-6.63% SMA20020.11% Volume249,324 Change-0.15%
Nov-19-19Reiterated H.C. Wainwright Buy $22 → $30
Oct-29-19Initiated Robert W. Baird Outperform
May-24-19Resumed Citigroup Buy $30
Jan-22-19Upgrade Chardan Capital Markets Neutral → Buy $18
Nov-06-18Upgrade B. Riley FBR Neutral → Buy $13.50 → $21
Sep-13-18Initiated Citigroup Buy $27
Aug-15-18Upgrade H.C. Wainwright Neutral → Buy $21
Aug-09-18Reiterated Stifel Buy $18 → $20
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $10
Mar-23-18Downgrade H.C. Wainwright Buy → Neutral $12
Mar-09-18Initiated Chardan Capital Markets Neutral
Feb-05-18Initiated SunTrust Buy $13
Jan-16-18Initiated Evercore ISI Outperform $14
Nov-03-17Reiterated H.C. Wainwright Buy $6 → $10
May-23-17Resumed H.C. Wainwright Buy $5
Apr-10-17Reiterated H.C. Wainwright Buy $8 → $5
Jan-31-17Resumed Leerink Partners Mkt Perform
Dec-12-16Initiated H.C. Wainwright Buy $7
Aug-15-16Reiterated Chardan Capital Markets Neutral $4 → $3.50
Aug-08-16Reiterated Chardan Capital Markets Neutral $4 → $3.50
Feb-20-20 04:05PM  Dicerna to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020 Business Wire
Feb-18-20 04:05PM  Dicerna to Present at Upcoming Investor Conferences Business Wire
Feb-10-20 07:30AM  Dicerna Appoints Stephen Doberstein, Ph.D., to Board of Directors Business Wire +6.21%
Feb-03-20 04:30PM  Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-29-20 12:45PM  3 Charts Suggest Micro-Cap Stocks Are Headed Higher Investopedia
Jan-17-20 05:40PM  Pharma and Biotech Arent Worried About Democratic Candidates Attacks Against Drugmakers Barrons.com
Jan-02-20 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
08:10AM  Dow Jones Futures Signal Gains To Start 2020: Tesla Deliveries Loom; Google, Disney Test Key Support Investor's Business Daily
07:30AM  Dicerna Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases Business Wire
Jan-01-20 07:40AM  We've made it to 2020. These are the top business issues to look for in the new year American City Business Journals
Dec-19-19 07:30AM  Dicerna Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection Business Wire
Dec-18-19 11:03AM  Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU Zacks
Dec-17-19 04:12PM  Biotech Succeeds With Gene-Silencing Drug But Its Stock Rally Fails Investor's Business Daily
07:30AM  Dicerna Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency Business Wire
06:00AM  Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-16-19 08:00AM  Alexion Exercises Option for Two Additional GalXC RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna Business Wire
Dec-15-19 08:46AM  The Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price Has Soared 805%, Delighting Many Shareholders Simply Wall St.
Dec-08-19 03:46PM  Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Dec-03-19 08:29AM  Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1% Zacks
Dec-02-19 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +10.06%
Nov-26-19 04:05PM  Dicerna to Present at Evercore ISI 2nd Annual HealthCONx Conference Business Wire
Nov-25-19 04:21PM  Edited Transcript of DRNA earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents +5.51%
Nov-19-19 07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga +12.20%
Nov-18-19 06:00AM  Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases Business Wire +10.83%
Nov-15-19 12:30PM  Drug giant Roche acquires Lexington biotech for $390M American City Business Journals
Nov-13-19 04:05PM  Dicerna to Present at the Stifel 2019 Healthcare Conference Business Wire
Nov-07-19 04:05PM  Dicerna Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress Business Wire
Nov-04-19 07:30AM  Dicerna to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019 Business Wire
Nov-01-19 08:06PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 06:30AM  Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
06:30AM  Dicerna Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection Business Wire
Oct-28-19 04:13PM  Is Dicerna Pharmaceuticals Inc (DRNA) A Good Stock To Buy? Insider Monkey
10:32AM  Dicerna Pharmaceuticals (DRNA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-01-19 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-25-19 09:02PM  Edited Transcript of DRNA earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
04:05PM  Dicerna to Present at Two Upcoming Investor Conferences Business Wire
Sep-19-19 04:05PM  Dicerna Appoints Patrick Gray to Board of Directors to Support Continued Growth Business Wire
Sep-16-19 07:58AM  How Should Investors Feel About Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO Pay? Simply Wall St.
Sep-04-19 04:05PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-03-19 04:05PM  Dicerna to Present at H.C. Wainwright 21st Annual Global Investment Conference Business Wire
03:20AM  3 Biopharma Stocks With Over 50% Upside TipRanks
Aug-28-19 03:16PM  Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
Aug-15-19 09:00AM  BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
Aug-09-19 08:05PM  Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 04:05PM  Dicerna Reports Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Aug-02-19 04:05PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-01-19 04:05PM  Dicerna to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019 Business Wire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-15-19 07:30AM  Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1) Business Wire
Jul-07-19 11:19AM  5 Stocks With Over 20% Upside Potential, Say Top Analysts TipRanks
Jul-02-19 07:00AM  RNAi startup Dicerna developing new liver drug American City Business Journals -5.32%
07:00AM  Dicerna to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Business Wire
Jul-01-19 04:30PM  Dicerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-21-19 07:30AM  Dicerna Presents Additional Data from PHYOX1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2) Business Wire
Jun-20-19 07:30AM  Globally Recognized Nephrologist Joins Dicerna to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria Business Wire
Jun-18-19 11:45AM  Did The Underlying Business Drive Dicerna Pharmaceuticals's (NASDAQ:DRNA) Lovely 393% Share Price Gain? Simply Wall St.
Jun-13-19 07:30AM  Dicerna Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy Business Wire
Jun-12-19 04:04PM  Bain's second life sciences fund comes in over $1 billion American City Business Journals +5.63%
Jun-11-19 06:57PM  Heres What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Jun-04-19 07:30AM  Dicerna Appoints Rob Ciappenelli Chief Commercial Officer Business Wire
Jun-03-19 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-28-19 04:05PM  Dicerna to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-16-19 07:30AM  Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus Business Wire
May-12-19 06:10AM  Edited Transcript of DRNA earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 09:24PM  Dicerna Pharmaceuticals Inc (DRNA) Q1 2019 Earnings Call Transcript Motley Fool
07:15PM  Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:07PM  Dicerna Pharmaceuticals: 1Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports First Quarter 2019 Financial and Operating Results and Provides Corporate Update Business Wire
May-07-19 11:47AM  Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey -7.13%
May-03-19 04:05PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-02-19 04:05PM  Dicerna to Report First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019 Business Wire
07:30AM  Dicerna Submits Updated IND Application for DCR-PHXC for Treatment of Primary Hyperoxaluria (PH) for the PHYOX2 Pivotal Trial Business Wire
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-01-19 04:30PM  Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
04:05PM  Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-29-19 06:30AM  Dicerna Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2) Business Wire
Mar-15-19 05:41AM  Edited Transcript of DRNA earnings conference call or presentation 11-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-11-19 09:28PM  Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript Motley Fool +7.41%
05:35PM  Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:42PM  Dicerna Pharmaceuticals: 4Q Earnings Snapshot Associated Press
04:05PM  Dicerna Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update Business Wire
02:30PM  Dicerna Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-06-19 08:30AM  New Research: Key Drivers of Growth for Energy Transfer LP, Domo, Accenture, Chevron, Cincinnati Financial, and Dicerna Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -6.11%
Mar-04-19 04:05PM  Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019 Business Wire
Mar-01-19 04:30PM  Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +5.90%
Feb-22-19 04:49PM  Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-21-19 09:10AM  ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth Business Wire
Feb-12-19 01:17PM  Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer PR Newswire
Feb-05-19 07:35AM  Recent Analysis Shows DICK'S Sporting Goods, Zix, Q2, InfraREIT, The Boston Beer, and Dicerna Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-01-19 04:30PM  Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-28-19 07:30AM  Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus Business Wire
Jan-24-19 07:30AM  Dicerna Evolves Its Board of Directors to Support Continued Growth Business Wire
Jan-23-19 12:13AM  Edited Transcript of DRNA earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -5.76%
Jan-08-19 04:05PM  Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-04-19 07:00AM  Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna Business Wire +8.63%
Dec-20-18 07:30AM  Dicerna to Join NASDAQ Biotechnology Index Business Wire
Dec-19-18 07:30AM  Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company Business Wire
Dec-15-18 11:06PM  Here is What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brown Bob DSee RemarksFeb 10Option Exercise3.428,18527,99313,185Feb 11 08:01 PM
Brown Bob DSee RemarksFeb 10Sale21.008,185171,8855,000Feb 11 08:01 PM
Weissman James BEVP & Chief Operating OfficerFeb 03Option Exercise2.974,36012,94926,220Feb 04 08:03 PM
Weissman James BEVP & Chief Operating OfficerFeb 03Sale20.204,36088,07221,860Feb 04 08:03 PM
GREEN JOHN BChief Financial OfficerJan 17Option Exercise2.9747,969142,46867,390Jan 21 08:00 PM
GREEN JOHN BChief Financial OfficerJan 17Sale21.2747,9691,020,16419,421Jan 21 08:00 PM
Weissman James BEVP & Chief Operating OfficerJan 02Option Exercise3.124,36013,62426,220Jan 03 08:00 PM
Weissman James BEVP & Chief Operating OfficerJan 02Sale21.884,36095,37621,860Jan 03 08:00 PM
Brown Bob DSee RemarksDec 31Option Exercise3.1016,94152,56516,941Dec 31 07:00 PM
Brown Bob DSee RemarksDec 31Sale22.0011,941262,7025,000Dec 31 07:00 PM
Brown Bob DSee RemarksDec 30Option Exercise3.2513,13642,69722,806Dec 31 07:00 PM
Brown Bob DSee RemarksDec 30Sale21.8522,806498,4010Dec 31 07:00 PM
ROSSKAMP RALFChief Medical OfficerDec 26Option Exercise2.9120,00058,20023,564Dec 27 08:08 PM
ROSSKAMP RALFChief Medical OfficerDec 26Sale22.6920,000453,7643,564Dec 27 08:08 PM
FAMBROUGH DOUGLASChief Executive OfficerDec 18Option Exercise3.4280,000273,60092,300Dec 19 08:54 PM
Weissman James BEVP & Chief Operating OfficerDec 18Option Exercise9.0911,00199,99925,705Dec 19 08:34 PM
FAMBROUGH DOUGLASChief Executive OfficerDec 18Sale25.8780,0002,069,58612,300Dec 19 08:54 PM
FAMBROUGH DOUGLASChief Executive OfficerDec 17Sale26.1759,0211,544,34512,300Dec 19 08:54 PM
GREEN JOHN BChief Financial OfficerDec 11Option Exercise5.458,00043,60018,698Dec 11 08:00 PM
Koppel AdamDirectorDec 04Sale24.681,500,00037,020,0004,080,237Dec 06 05:00 PM
Weissman James BEVP & Chief Operating OfficerDec 02Option Exercise2.9720,00059,40034,704Dec 03 08:00 PM
Weissman James BEVP & Chief Operating OfficerDec 02Sale26.0020,000520,00014,704Dec 03 08:00 PM
Kolchinsky PeterDirectorDec 02Sale24.98137,1763,427,1370Dec 02 04:30 PM
Kolchinsky PeterDirectorNov 29Sale24.22138,0003,341,725137,176Dec 02 04:30 PM
Kolchinsky PeterDirectorNov 27Sale24.04368,7008,864,765275,176Dec 02 04:30 PM
Kolchinsky PeterDirectorNov 26Sale23.59239,7005,653,444643,876Nov 26 05:23 PM
GREEN JOHN BChief Financial OfficerNov 25Option Exercise5.4512,50068,12523,198Nov 27 08:00 PM
GREEN JOHN BChief Financial OfficerNov 25Sale24.9512,500311,87510,698Nov 27 08:00 PM
Kolchinsky PeterDirectorNov 25Sale24.06361,2008,689,677883,576Nov 26 05:23 PM
Kolchinsky PeterDirectorNov 22Sale22.52197,7004,451,4921,244,776Nov 26 05:23 PM
Kolchinsky PeterDirectorNov 21Sale22.98351,5058,076,9521,442,476Nov 21 05:02 PM
Kolchinsky PeterDirectorNov 20Sale22.93265,5056,088,8791,793,981Nov 21 05:02 PM
Weissman James BEVP & Chief Operating OfficerNov 19Option Exercise3.4220,00068,40034,704Nov 20 08:02 PM
Kolchinsky PeterDirectorNov 19Sale23.92397,1839,501,2932,059,486Nov 21 05:02 PM
Bain Capital Life Sciences Inv10% OwnerNov 19Sale22.031,750,00038,552,5005,580,237Nov 21 04:26 PM
Weissman James BEVP & Chief Operating OfficerNov 19Sale24.0020,000480,00014,704Nov 20 08:02 PM
GREEN JOHN BChief Financial OfficerNov 18Option Exercise5.4512,50068,12523,198Nov 20 08:00 PM
Weissman James BEVP & Chief Operating OfficerNov 18Option Exercise3.4220,00068,40034,704Nov 20 08:02 PM
Weissman James BEVP & Chief Operating OfficerNov 18Sale22.0020,000440,00014,704Nov 20 08:02 PM
GREEN JOHN BChief Financial OfficerNov 18Sale21.0512,500263,12510,698Nov 20 08:00 PM
Weissman James BEVP & Chief Operating OfficerNov 14Option Exercise3.4220,00068,40034,704Nov 15 08:03 PM
Weissman James BEVP & Chief Operating OfficerNov 14Sale20.0020,000400,00014,704Nov 15 08:03 PM
GREEN JOHN BChief Financial OfficerNov 14Sale20.003,56271,24010,698Nov 15 08:01 PM
Weissman James BEVP & Chief Operating OfficerOct 31Option Exercise3.4215,00051,30029,704Nov 01 07:00 PM
GREEN JOHN BChief Financial OfficerOct 31Option Exercise5.4512,50068,12526,760Nov 01 07:03 PM
GREEN JOHN BChief Financial OfficerOct 31Sale18.0012,500225,00014,260Nov 01 07:03 PM
Weissman James BEVP & Chief Operating OfficerOct 31Sale18.0015,000270,00014,704Nov 01 07:00 PM
Weissman James BEVP & Chief Operating OfficerOct 18Option Exercise3.424,90416,77214,704Oct 18 07:30 PM
Weissman James BChief Business OfficerAug 23Sale13.0714,680191,8329,800Aug 23 08:31 PM
Bain Capital Life Sciences InvDirectorMay 29Sale12.501,600,00020,000,0007,330,237May 31 04:15 PM
Weissman James BChief Business OfficerApr 02Option Exercise3.4215,00051,30039,480Apr 04 08:00 PM
Weissman James BChief Business OfficerApr 02Sale15.0015,000225,00024,480Apr 04 08:00 PM